Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396554 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 | |
| SCHEMBL21649014 | 0.87 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2HSD11B1NPC1LMNA | |
| SCHEMBL8255174 | 0.85 | NR1H2 (0.42) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 | |
| SCHEMBL934024 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 | |
| SCHEMBL14488388 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 | |
| SCHEMBL16824583 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 | |
| SCHEMBL2905429 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2EPHX2USP2 | |
| SCHEMBL2905427 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2EPHX2USP2 | |
| SCHEMBL16584822 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2EPHX2USP2 | |
| SCHEMBL2126924 | 0.84 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2HSD11B1EPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076383-A1 | SULFONANILIDE AND BENZYLSULFONYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3083562-B1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3083562-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| CN-105793242-A | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators | 伊莱利利公司 | 2016-07-20 | — | — | CN | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015094902-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| EP-2729445-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| CN-103702980-A | Cyclic amine derivatives as EP4Receptor antagonists | ROTTAPHARM SPA | 2014-04-02 | — | — | CN | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
| US-5521175-A | CHOLECYSTOKININS AND GASTRIN ANTAGONIST FOR PHYSIOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0652873-A1 | BENZODIAZEPINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994003447-A1 | BENZODIAZEPINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | HSD17B10 3686/4885SMN1; SMN2 4442/4885HSD11B1 1374/4885 |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | HSD17B10 4150/4885SMN1; SMN2 4790/4885HSD11B1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.